Stockholm - Delayed Quote • SEK
Vicore Pharma Holding AB (publ) (VICO.ST)
At close: April 23 at 5:29 PM GMT+2
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Cash Flow
-249,583.00
-249,583.00
-299,919.00
-265,171.00
-119,935.00
Investing Cash Flow
-144,455.00
-144,455.00
74,000.00
-7,000.00
4,000.00
Financing Cash Flow
470,855.00
470,855.00
187,040.00
318,183.00
176,967.00
End Cash Position
333,620.00
333,620.00
256,803.00
294,199.00
248,618.00
Capital Expenditure
--
--
-3,000.00
--
-3,000.00
Issuance of Capital Stock
500,406.00
500,406.00
200,000.00
336,000.00
187,550.00
Free Cash Flow
-249,583.00
-249,583.00
-302,919.00
-265,171.00
-122,935.00
12/31/2020 - 12/10/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
EGTX.ST Egetis Therapeutics AB (publ)
6.28
+0.32%
CALTX.ST Calliditas Therapeutics AB (publ)
100.40
+0.10%
BIOA-B.ST BioArctic AB (publ)
188.40
+2.06%
6A3A.F Autolus Therapeutics plc
4.2200
+0.48%
IF0.F InflaRx N.V.
1.3420
+10.63%
NANOFS.ST Nanoform Finland Oyj
30.35
-3.19%
DMYD-B.ST Diamyd Medical AB (publ)
9.60
+3.45%
ACE.ST Ascelia Pharma AB (publ)
12.54
-1.72%
CANTA.ST Cantargia AB (publ)
3.7000
-0.80%
B9A.F BioArctic AB (publ)
15.79
-6.18%